Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

COVID-19 Vaccines*/immunology ; COVID-19*/prevention & control ; COVID-19*/immunology ; Technology Transfer* ; SARS-CoV-2*/immunology; Humans ; Iran ; Male ; Female ; Immunogenicity, Vaccine ; Adult ; Middle Aged ; Cuba ; Young Adult

During COVID-19 pandemic, international pharmaceutical companies put effort to build global manufacturing networks for vaccines. Soberana Plus vaccine, a recombinant protein based vaccine (RBD dimer), with the trade name of PastoCovac Plus in Iran, is based on a protein subunit platform in Cuba and completed preclinical and toxicological assessments. This study aimed at presenting the steps of vaccine technology transfer from Cuba to Iran. This study provides the first practical comparability results in Iran to ensure the quality, safety and efficacy of a protein subunit vaccine against COVID-19 after a successful technology transfer from Cuba. PastoCovac Plus was transferred to Iran at the formulation stage. The assessment of the active ingredient pharmaceutical (API) was achieved through physicochemical and clinical data collection and tests to assure if there was any adverse impact on the vaccination results. In order to assess the quality of the vaccine product after technology transfer, we sought different properties including regulatory features, physicochemical quality, vaccine potency and stability as well as its immunogenicity and safety. Following the evaluation of the clinical quality attributes (CQAs) based on the standard protocols, the results showed that the two vaccines are highly similar and comparable, with no considerable effect on safety or efficacy profiles. The CQAs were all in the acceptance limits in terms of safety and efficacy as well as clinical evaluation results. The immunogenicity evaluation also confirmed no significant differences between the vaccines regarding reinfection (P = 0.199) or vaccine breakthrough (P = 0.176). Furthermore, the level of anti-spike and neutralizing antibodies in the both vaccine groups was not significantly different indicating the equality of performance between the two vaccines. According to the results of the quality and clinical assessment of this study, we achieved an acceptable quality attributes and acceptant limits in terms of safety and efficacy of the vaccines pre and post technology transfer.
(© 2024. The Author(s).)

Koirala, A., Joo, Y. J., Khatami, A., Chiu, C. & Britton, P. N. Vaccines for COVID-19: the current state of play. Paediatr. Respir. Rev. 35, 43–49 (2020). (PMID: 326534637301825)
Funk, C. D., Laferrière, C. & Ardakani, A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front. Pharmacol. 11, 937 (2020). (PMID: 10.3389/fphar.2020.00937326367547317023)
Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382(21), 1969–1973 (2020). (PMID: 10.1056/NEJMp200563032227757)
Carneiro, D. C., Sousa, J. D. & Monteiro-Cunha, J. P. The COVID-19 vaccine development: A pandemic paradigm. Virus Res. 301, 198454 (2021). (PMID: 10.1016/j.virusres.2021.19845434015363)
Yamey, G. et al. It is not. too late to achieve global covid-19 vaccine equity. BMJ 376, o812 (2022).
Krishtel, P. & Hassan, F. Share Vaccine Know-How 379 (American Association for the Advancement of Science, 2021).
Friede, M. et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transfer. Vaccine 29, A2–A7 (2011).
Bown, C. P. & Bollyky, T. J. How COVID-19 vaccine supply chains emerged in the midst of a pandemic. World Econ. 45(2), 468–522 (2022).
Fonseca, E. M. D., Shadlen, K. C. & Achcar, H. M. Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions. Res. Policy 52(4), 104739 (2023).
Forman, R., Shah, S., Jeurissen, P., Jit, M. & Mossialos, E. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy 125(5), 553–567 (2021). (PMID: 10.1016/j.healthpol.2021.03.013)
Maslehat, S., Doroud, D. & Mostafavi, E. A leading institute in the production and development of vaccines in Iran. Vacres 6(1), 33–42 (2019). (PMID: 10.29252/vacres.6.1.33)
Optimism as Cuba set to test its own Covid vaccine [Internet]. BBC News. https://www.bbc.com/news/world-latin-america-56069577 (2023).
Mostafavi, E. et al. Efficacy and safety of a protein-based SARS-CoV-2 vaccine: A randomized clinical trial. JAMA Netw. Open. 6(5), e2310302 (2023). (PMID: 10.1001/jamanetworkopen.2023.103023713386410157429)
Pérez-Rodríguez, S. et al. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. Vaccine 40(13), 2068–2075 (2022). (PMID: 10.1016/j.vaccine.2022.02.029351649868823954)
Toledo-Romani, M. E. et al. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med. (New York NY) 3(11), 760–773 (2022).
Ghanei, M. et al. Exploring the experience of developing COVID-19 vaccines in Iran. Clin. Exp. Vacc. Res. 12(1), 1–12 (2023). (PMID: 10.7774/cevr.2023.12.1.1)
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581(7807), 221–224 (2020).
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581(7807), 215–220 (2020). (PMID: 10.1038/s41586-020-2180-532225176)
Krammer, F. SARS-CoV-2 vaccines in development. Nature 586(7830), 516–527 (2020).
Valdes-Balbin, Y. et al. Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines. ACS Cent. Sci. 7(5), 757–767 (2021). (PMID: 10.1021/acscentsci.1c00216340753458084267)
Zang, J. et al. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell. Discov. 6(1), 61 (2020).
Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Sci. (New York NY) 369(6504), 643–650 (2020). (PMID: 10.1126/science.abc5902)
Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Sci. (New York NY) 369(6506), 956–963 (2020). (PMID: 10.1126/science.abc7520)
Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584(7821), 443–449 (2020). (PMID: 10.1038/s41586-020-2548-6326684437584396)
Rutten, L. et al. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity. Sci. Rep. 14(1), 5735 (2024). (PMID: 10.1038/s41598-024-56293-x3845908610923862)
http://www.emea.eu.int/pdfs/human/bwp/320702en.pdf . https://www.ema.europa.eu/en/documents/scientific-guideline/comparability-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality/ich/5721/03_en.pdf (2003).
http://www.emea.eu.int/pdfs/human/bwp/320700en.pdf . https://www.ema.europa.eu/en/documents/scientific-guideline/comparability-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality/ich/5721/03_en.pdf (2003).
Alasandro, M. et al. Meeting report: Vaccine stability considerations to enable rapid development and deployment. AAPS Open. 7(1), 6 (2021). (PMID: 10.1186/s41120-021-00042-1348698308632204)
Usach, I., Martinez, R., Festini, T. & Peris, J-E. Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site. Adv. Therapy 36(11), 2986–2996 (2019).
Farahmand, B. et al. Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine. Heliyon 9(10), e20555 (2023).
Ramezani, A. et al. PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. Sci. Rep. 13(1), 8065 (2023).
Percie du Sert, N. et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 18(7), e3000411 (2020). (PMID: 10.1371/journal.pbio.3000411326632217360025)
Valdes-Balbin, Y. et al. Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines. ACS Central Sci. 7(5), 757–767 (2021).
Chang-Monteagudo, A. et al. A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. Lancet Reg. Health Am. 2021(4), 100079 (2021).
Santana-Mederos, D. et al. A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. RSC Chem. Biol.. 3(2), 242–249 (2022). (PMID: 10.1039/D1CB00200G35360883)
Hassan, P. M. et al. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein. Vaccine 40(20), 2856–2868 (2022). (PMID: 10.1016/j.vaccine.2022.03.06635393148)
Pichichero, M. E. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum. Vacc. Immunother. 9(12), 2505–2523 (2013). (PMID: 10.4161/hv.26109)
Chang-Monteagudo, A. et al. A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. Lancet Reg. Health Am. 4, 100079 (2021). (PMID: 345415718442527)
Ochoa-Azze, R. et al. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. Lancet Respiratory Med. 10(8), 785–795 (2022). (PMID: 10.1016/S2213-2600(22)00100-X)
Toledo-Romaní, M. E. et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. Lancet Reg. Health Americas 2033, 45 (2023).
Annex 3 Guidelines on stability evaluation of vaccines. WHO Expert Committee on Biological Standardization (2011).
Interim recommendations for use of the ChAdOx1-S. [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [Internet]. World Health Organization. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1 (2023).

Keywords: Iran; PastoCovac Plus; Protein-based vaccine; RBD dimer; Soberana Plus

0 (COVID-19 Vaccines)

Date Created: 20241105 Date Completed: 20241105 Latest Revision: 20241108

20250114

PMC11538526

10.1038/s41598-024-77331-8

39501012